Login to Your Account

Therapy May Correct Underlying Damage

Scil Technology to Bank $239M+ In Osteoarthritis Deal with Sanofi

By Nuala Moran
BioWorld International Correspondent

Wednesday, December 21, 2011
LONDON – Scil Technology GmbH has signed up Sanofi SA as commercialization partner for its protein therapy for osteoarthritis in a €180 million (US$235.9 million) plus royalties deal that will see the French pharma company take on all responsibility for further development of the program.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription